~~<i id='00A7C620D6'><strike id='00A7C620D6'><tt id='00A7C620D6'><pre id='00A7C620D6'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：leisure time 2025-10-06 16:59:01 Page View：6

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Elizabeth Warren probes abortion access
Next article： 23andMe had bad news about my health. I wish a person had delivered it

explore

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

HIPAA doesn't protect reproductive records from prosecutors

HyacinthEmpinado/STATWithRoev.Wadenowoverturned,patientsarewonderingwhetherfederallawswillshieldthei

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Gain of function research would be limited under House proposal

Rep.ThomasMassie(R-Ky.)KevinDietsch/GettyImagesWASHINGTON—HouselawmakerslateTuesdayvotedtoattachaU.S